Helena Chaye Email

CEO . KaliVir Immunotherapeutics

Current Roles

Employees:
45
Revenue:
$4.5M
About
KaliVir Immunotherapeutics was founded in 2019 to pioneer a unique and novel approach to cancer treatment that engages a virus’ natural ability to replicate in and kill cancer cells. This modality is known as oncolytic viral immunotherapy. KaliVir’s cutting-edge, next generation oncolytic viral immunotherapy programs combine technologies developed in-house and licensed from University of Pittsburgh’s world-class oncolytic virus and immunotherapy research programs.
KaliVir Immunotherapeutics Address
240 Alpha Drive
Pittsburgh, PA
United States
KaliVir Immunotherapeutics Email
KaliVir Immunotherapeutics Phone Numbers
+14124356730